Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Marwan Fakih

Showing results (181-190 of 200) with videos related to

Pageof 20
Sort By:
Lancet (London, England)|June 14, 2025
Retifanlimab with carboplatin and paclitaxel for locally recurrent or metastatic squamous cell carcinoma of the anal canal (POD1UM-303/InterAACT-2): a global, phase 3 randomised controlled trialSheela Rao, Emmanuelle Samalin-Scalzi, Ludovic Evesque, et al.
Science Translational Medicine|August 10, 2022
Adenoviral-based vaccine promotes neoantigen-specific CD8<sup>+</sup> T cell stemness and tumor rejectionAnna Morena D'Alise, Nadia Brasu, Carlo De Intinis, et al.
European Journal of Cancer (Oxford, England : 1990)|July 21, 2025
Prognostic impact of the BRAF V600E mutation in patients with MSI-high metastatic colorectal cancer treated with immune checkpoint inhibitorsClaire Gallois, Margherita Ambrosini, Sara Lonardi, et al.
The Lancet. Oncology|May 7, 2021
Trastuzumab deruxtecan (DS-8201) in patients with HER2-expressing metastatic colorectal cancer (DESTINY-CRC01): a multicentre, open-label, phase 2 trialSalvatore Siena, Maria Di Bartolomeo, Kanwal Raghav, et al.
Annals of Surgical Oncology|July 27, 2023
Safety and Efficacy of Oxaliplatin Pressurized Intraperitoneal Aerosolized Chemotherapy (PIPAC) in Colorectal and Appendiceal Cancer with Peritoneal Metastases: Results of a Multicenter Phase I Trial in the USAMustafa Raoof, Richard L Whelan, Kevin M Sullivan, et al.
The Lancet. Oncology|September 13, 2020
Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 studyAurélien Marabelle, Marwan Fakih, Juanita Lopez, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 6, 2025
Trastuzumab Plus Pertuzumab Versus Cetuximab Plus Irinotecan in Patients With <i>RAS/BRAF</i> Wild-Type, HER2-Positive, Metastatic Colorectal Cancer (S1613): A Randomized Phase II TrialKanwal Pratap Singh Raghav, Katherine A Guthrie, Benjamin Tan, et al.
The Lancet. Gastroenterology & Hepatology|February 3, 2022
Pembrolizumab for previously treated advanced anal squamous cell carcinoma: results from the non-randomised, multicohort, multicentre, phase 2 KEYNOTE-158 studyAurelien Marabelle, Philippe A Cassier, Marwan Fakih, et al.
Eclinicalmedicine|April 24, 2023
Regorafenib plus nivolumab in patients with mismatch repair-proficient/microsatellite stable metastatic colorectal cancer: a single-arm, open-label, multicentre phase 2 studyMarwan Fakih, Kanwal Pratap Singh Raghav, David Z Chang, et al.
Cancer Discovery|November 30, 2018
A Phase I/Ib Trial of the VEGFR-Sparing Multikinase RET Inhibitor RXDX-105Alexander Drilon, Siqing Fu, Manish R Patel, et al.
Pageof 20

Showing results (181-190 of 200) with videos related to

Sort By:
Pageof 20
Lancet (London, England)|June 14, 2025
Retifanlimab with carboplatin and paclitaxel for locally recurrent or metastatic squamous cell carcinoma of the anal canal (POD1UM-303/InterAACT-2): a global, phase 3 randomised controlled trialSheela Rao, Emmanuelle Samalin-Scalzi, Ludovic Evesque, et al.
Science Translational Medicine|August 10, 2022
Adenoviral-based vaccine promotes neoantigen-specific CD8<sup>+</sup> T cell stemness and tumor rejectionAnna Morena D'Alise, Nadia Brasu, Carlo De Intinis, et al.
European Journal of Cancer (Oxford, England : 1990)|July 21, 2025
Prognostic impact of the BRAF V600E mutation in patients with MSI-high metastatic colorectal cancer treated with immune checkpoint inhibitorsClaire Gallois, Margherita Ambrosini, Sara Lonardi, et al.
The Lancet. Oncology|May 7, 2021
Trastuzumab deruxtecan (DS-8201) in patients with HER2-expressing metastatic colorectal cancer (DESTINY-CRC01): a multicentre, open-label, phase 2 trialSalvatore Siena, Maria Di Bartolomeo, Kanwal Raghav, et al.
Annals of Surgical Oncology|July 27, 2023
Safety and Efficacy of Oxaliplatin Pressurized Intraperitoneal Aerosolized Chemotherapy (PIPAC) in Colorectal and Appendiceal Cancer with Peritoneal Metastases: Results of a Multicenter Phase I Trial in the USAMustafa Raoof, Richard L Whelan, Kevin M Sullivan, et al.
The Lancet. Oncology|September 13, 2020
Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 studyAurélien Marabelle, Marwan Fakih, Juanita Lopez, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 6, 2025
Trastuzumab Plus Pertuzumab Versus Cetuximab Plus Irinotecan in Patients With <i>RAS/BRAF</i> Wild-Type, HER2-Positive, Metastatic Colorectal Cancer (S1613): A Randomized Phase II TrialKanwal Pratap Singh Raghav, Katherine A Guthrie, Benjamin Tan, et al.
The Lancet. Gastroenterology & Hepatology|February 3, 2022
Pembrolizumab for previously treated advanced anal squamous cell carcinoma: results from the non-randomised, multicohort, multicentre, phase 2 KEYNOTE-158 studyAurelien Marabelle, Philippe A Cassier, Marwan Fakih, et al.
Eclinicalmedicine|April 24, 2023
Regorafenib plus nivolumab in patients with mismatch repair-proficient/microsatellite stable metastatic colorectal cancer: a single-arm, open-label, multicentre phase 2 studyMarwan Fakih, Kanwal Pratap Singh Raghav, David Z Chang, et al.
Cancer Discovery|November 30, 2018
A Phase I/Ib Trial of the VEGFR-Sparing Multikinase RET Inhibitor RXDX-105Alexander Drilon, Siqing Fu, Manish R Patel, et al.
Pageof 20